Dr. Panachai Silpsamrit

Dr. Panachai Silpsamrit

Consultant 

9 Years of Experience

Bone Marrow Transplant Surgeon, Hematologist

MD, Diploma

Vejthani Hospital, Bangkok

English, Thai

Consultation Fee $ 27

Book an Appointment

About Dr. Panachai Silpsamrit

  • Dr. Panachai Silpsamrit is a hematologist and BMT specialist with 9 years of experience. 
  • He is well-versed in dealing with myeloma and disorders like sickle cell disease and ?-thalassemia. 
  • He is also proficient in stem cell therapy and transplantation.  
  • Dr. Panachai Silpsamrit obtained an MD in Medicine from Chulalongkorn University, Thailand, in 2015. 
  • He also gained a Diploma in Hematology from Phramongkutklao Hospital, Thailand, in 2019. 
  • Further, he earned a Certificate in Hematopoietic Stem Cell Transplantation in adult patients in 2022. 
  • He is a member of the Medical Council of Thailand and the Thai Society of Hematology of Thailand, as well as subcommittees like the Thai Red Cell Disorder and Aplastic Anemia Working Group. 

Book Your Appointment With Dr. Panachai Silpsamrit

Get a Treatment Plan Within 1 Hour

Education

  • MD in Medicine, Chulalongkorn University, Thailand, 2015
  • Diploma in Hematology, Phramongkutklao hospital, Thailand, 2019

Training & Certificates

  • Certificate in Hematopoietic Stem Cell Transplantation in adult patients, 2022

Associations/Membership

  • Medical Council of Thailand
  • Thai Society of Hematology of Thailand
  • Thai Multiple Myeloma Working Group
  • Thai Red Cell Disorder and Aplastic Anemia Working Group
  • Thai Adult Acute Leukemia Working Group

Paper Published

  • Apipongrat, D., Roytrakul, S., Prayongratana, K., Charoenpitakchai, M., Intharanut, K., Laoruangroj, C., ... & Nathalang, O. (2022). Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma. Plos one, 17(12), e0278464.
  • Frangoul, H., Bobruff, Y., Cappellini, M. D., Corbacioglu, S., Fernandez, C. M., De la Fuente, J., ... & Wall, D. (2020). Safety and efficacy of CTX001 in patients with transfusion-dependent ?-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells. Blood, 136, 3-4

Field of Expertise

  • Allogeneic Bone Marrow Transplant
  • Autologous Bone Marrow Transplant
  • Haplo–Allogeneic Bone Marrow Transplant
  • Hematopoietic Stem Cell Transplantation (HPSCT)
  • Pediatric Bone Marrow Transplant
  • Stem Cell Transplant
  • Anemia
  • Aplastic Anemia
  • Chronic Granulomatous Disease (CGD)
  • Diamond-Blackfan Anemia (DBA)
  • Dyskeratosis Congenita (DKC)
  • Eosinophilic Disorders
  • Essential Thrombocythemia
  • Fanconi Anemia (FA)
  • Hemochromatosis
  • Hemolytic Anemia
  • Hemophilia
  • Hereditary Spherocytosis
  • Hodgkin Lymphoma
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inherited Bone Marrow Failure Syndromes (IBMFS)
  • Iron-Deficiency Anemia
  • Langerhans Cell Histiocytosis (LHC)
  • Leukopenia
  • Mastocytosis
  • Monoclonal Gammopathy
  • Myelodysplastic Syndromes (MDS)
  • Myelofibrosis
  • Myeloproliferative Neoplasms (MPN)
  • Non-Hodgkin Lymphoma
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Pernicious Anemia
  • Polycythemia Vera
  • Porphyria
  • Post-Transplant Lymphoproliferative Disorder (PTLD)
  • Shwachman-Diamond syndrome (SDS)
  • Sickle Cell Anemia
  • Thalassemia
  • Thrombocytopenia
  • Thrombophilia
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • Venous Thromboembolism (VTE)
  • Von Willebrand Disease
  • Waldenstrom Macroglobulinemia